Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease

Abstract

Atherosclerotic renovascular disease (RVD) reduces renal blood flow (RBF) and GFR and accelerates poststenotic kidney (STK) tissue injury. Preclinical studies indicate that mesenchymal stem cells (MSCs) can stimulate angiogenesis and modify immune function in experimental RVD. We assessed the safety and efficacy of adding intra-arterial autologous adipose-derived MSCs into STK to standardized medical treatment in human subjects without revascularization. The intervention group (n=14) received a single infusion of MSC (1.0 × 10⁵ or 2.5 × 10⁵ cells/kg; n=7 each) plus standardized medical treatment; the medical treatment only group (n=14) included subjects matched for age, kidney function, and stenosis severity. We measured cortical and medullary volumes, perfusion, and RBF using multidetector computed tomography. We assessed tissue oxygenation by blood oxygen level–dependent MRI and GFR by iothalamate clearance. MSC infusions were well tolerated. Three months after infusion, cortical perfusion and RBF rose in the STK (151.8–185.5 ml/min, P=0.01); contralateral kidney RBF increased (212.7–271.8 ml/min, P=0.01); and STK renal hypoxia (percentage of the whole kidney with R2*>30/s) decreased (12.1% [interquartile range, 3.3%–17.8%] to 6.8% [interquartile range, 1.8%–12.9%], P=0.04). No changes in RBF occurred in medical treatment only subjects. Single-kidney GFR remained stable after MSC but fell in the medical treatment only group (−3% versus −24%, P=0.04). This first-in-man dose-escalation study provides evidence of safety of intra-arterial infusion of autologous MSCs in patients with RVD. MSC infusion without main renal artery revascularization associated with increased renal tissue oxygenation and cortical blood flow.

Atherosclerotic renovascular disease (RVD) reduces renal blood flow (RBF) and ultimately accentuates tissue hypoxia.¹ Severe reductions in RBF eventually lead to vascular rarefication, inflammatory injury oxidative stress, and loss of renal function,^2–4 which has been designated “ischemic nephropathy.”⁵ Many of these changes fail to reverse after restoring vessel patency alone,^4,6, thereby reinforcing the need for more effective alternative or adjunctive therapy.

Experimental studies in swine and rodent RVD models show that infusion of mesenchymal stem cells (MSC) is associated with increased microvascular density and GFR beyond that attainable with restoring blood flow alone.^7,8 Moreover, MSC administration leads to reductions in oxidative stress and renal inflammation that were not observed with revascularization alone.⁷ Whether these preclinical observations with MSC therapy extend to humans with atherosclerotic RVD is unknown.

The purpose of this initial study was to examine the safety and efficacy of intra-arterial injection of autologous adipose-derived MSC alone in a dose-escalation phase 1/2A study for patients with atherosclerotic RVD. We sought to evaluate RBF, cortical and medullary perfusion, GFR, and renal tissue oxygenation in poststenotic kidneys (STKs) and contralateral kidneys (CLKs) of patients with atherosclerotic RVD treated with intrarenal MSC and compared with a matched group of patients treated with standardized medical therapy alone.

Results

Study Cohort

Demographic and clinical features of the 28 patients with RVD studied are summarized in Table 1. There were no differences between groups in age, severity of stenosis, and pretreatment kidney function. Measured BP, weight, body mass index, and most biochemical values were also not different between groups.

Table 1.

Clinical, laboratory, and demographic data of medically treated atherosclerotic RVD patients with and without MSC

Characteristic	Medical (n=14)	Medical plus MSCs (n=14)	P Value
Men/womena	6:8	9:5	0.45
Age, yr	71.1±6.9	74.4±3.4	0.13
Creatinine, mg/dl	1.32±0.31	1.5±0.3	0.11
Iothalamate clearance GFR, ml/min	54.9±20.4	51.2±18.6	0.6
Stenotic artery U/S Doppler “peak systolic velocity,” cm/s	331±119.4	303.7±64.5	0.3
SBP, mmHg	138.6±17	145.2±14	0.26
DBP, mmHg	66.1±6.9	67.8±12.4	0.64
Weight, kg	77.2±16.7	86.2±17.8	0.17
BMI, kg/m2	27.4±4.5	30.8±4.9	0.07
Hemoglobin, g/dl	12.4±1.3	13.2±1.3	0.1
Hematocrit, %	37.3±3.3	39.9±3.9	0.07

Mean±SD. N, number of patients; U/S, ultrasound; SBP, systolic BP; DBP, diastolic BP; BMI, body mass index.

^aFisher exact test.

Safety Monitoring: Sequential Measurements after MSC Infusion

All patients tolerated the single MSC infusion without identified adverse clinical effects (specifically: fever, headache, vomiting, weakness, hematuria, or allergic reactions). On the day after intra-arterial infusion of MSC, serum creatinine rose slightly (1.52±0.35–1.72±0.45 mg/dl), persisting for 1 week and returning to baseline by 1 month (Table 2). Additionally, C-reactive protein (CRP) rose for 1 day (3.1±1.2–6.1±2.3), whereas lactate dehydrogenase was unchanged. White blood cell count and platelets rose slightly and remained above baseline for 1 month. These transient alterations in laboratory values resolved by the 3-month inpatient return visit. None of these were associated with evident pathology, discomfort, or adverse events. No changes occurred in neutrophil gelatinase-associated lipocalin (NGAL) or urine cytology during follow-up.

Table 2.

Safety data as reflected by sequential measurements after MSC infusion

Variable	Baseline	1 D	1 Wk	1 Mo	2 Mo	3 Mo
Creatinine mg/dl	1.52±0.35	1.72±0.45a	1.66±0.3a	1.55±0.37	1.55±0.33	1.53±0.3
CRP mg/L	3.1±1.2	6.1±2.3	4.1±5.1	3.3±4.4	2.3±1.7	3.4±2.3
LDH U/L	214±51	202±41	196±44	188±50.7a	185.2±53a	206.5±48
ESR mm/h	19.8±12.9					14.6±10.5
Leukocytes × 109/L	6.5±1.6	7.3±1.5a	7.2±1.4a	6.9±1.2a	6.7±1.2	6.6±1.3
Neutrophils × 109/L	3.8±1.3	4.65±1.2a	4.47±1.1a	4.17±1.1a	3.9±0.86	4.08±1.2
Platelets × 103/L	194±51	200±67a	245±67a	218.6±45a	212.6±60	196±44
NGAL ng/ml	204±64					208±45

Data are expressed as mean±SD. LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate; “Normal reference range ≤8 mg/L.”

^aP<0.05 versus baseline.

Cortical Perfusion and RBF Rose in MSC-Treated Kidneys

Results from quantitative multidetector computed tomography (MDCT) measurements of hemodynamics for individual STKs at baseline and after three months are summarized in Table 3. The total STK volume did not change in either medically-treated or MSC-treated groups. Both total RBF (Figure 1A) and cortical blood flow increased in the STKs, but medullary blood flow did not. Perfusion in the STKs rose in the MSC group from 2.02±0.69 to 2.4±1 ml/min per milliliter tissue (P=0.04) but remained unchanged in the medical treatment only group. Despite no direct intervention, changes of a similar magnitude were seen in cortical blood flow, total RBF, and cortical perfusion in the untreated CLKs in the MSC-treated group (Table 4) (Supplemental Figure 1 depicts individual changes in RBF). Whereas STK-iothalamate GFR (milliliter per minute per kidney) was unchanged in the MSC group (Table 3), the medical treatment group had a fall in STK-GFR at the 3-month follow-up (19 [13.8, 27.4] to 15.9 [9.7, 27.6] ml/min; P=0.05). When expressed as percent (%) change from baseline, the STK-GFR in the MSC group was unchanged (−3.3%) but fell in the medically treated group (−24.4%, P=0.04) (Figure 1B).

Table 3.

MDCT measurements of individual STK volume, tissue perfusion, blood flow, and iothalamate filtration

Single Kidney	Medically Treated STK (n=14)		MSC-Treated STK (n=14)
	Baseline	3 Mo	Baseline	3 Mo
Total kidney volume (CT), ml	90±42.9	86.6±41.3	98.9±41.2	98.9±41.3
Cortical volume, ml	59.7±27	56.3±28	61.2±31.8	61.8±29.6
Medullary volume, ml	30.3±17	30.3±16.2	37.8±12.7	37.2±13.3
Cortical perfusion, ml/min per milliliter of tissue	2.1±0.76	2.0±0.53	2.02±0.69	2.4±1a
Medullary perfusion, ml/min per milliliter of tissue	0.94±0.5	0.86±0.27	0.7±0.24	0.8±0.37
Total RBF, ml/minb	132.5 (96, 255)	128.1 (77.2, 233)	151.8 (63.7, 222)	185.5 (72.3, 259)a
Cortical blood flow, ml/minb	114 (75.7, 221)	106 (54, 186.3)	125.6 (54.7, 192)	138.3 (60.3, 226)a
Medullary blood flow, ml/minb	26.3 (11.5, 42.3)	20.3 (17.8, 36.4)	31 (14.8, 38.9)	29.4 (14.5, 36.9)
Single-kidney GFR, ml/min per kidneyb	19 (13.8, 27.4)	15.9 (9.7, 27.6)	20.4 (12, 25)	19.1 (14.3, 24.5)

CT, computed tomography.

^aP<0.05 versus baseline.

^bMedian (interquartile range) reported due to skewed data (both paired t test and Wilcoxon signed-rank test).

Figure 1.

MSC infusion increased STK-RBF and preserved GFR. Percent (%) change from baseline in STK-RBF and STK-GFR. (A) Differences in RBF (expressed as percent [%] change after 3 months) indicated a modest fall in RBF in the medically treated only group, whereas the MSC-treated group rose (P<0.05). (B) Relative change in measured STK-GFR decreased in medically treated group (−24.4%) during the 3-month follow-up but was preserved in the MSC group (−3.3%) (P<0.05). All patients received ACE/ARB treatment during these studies. ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; IQR, interquartile range.

Table 4.

MDCT measurements of individual CLK or untreated kidney volume, tissue perfusion, blood flow, and iothalamate filtration

Single Kidney	Medically Treated CLK (n=14)		MSC-Treated CLK (n=14)
	Baseline	3 Mo	Baseline	3 Mo
Total kidney volume (CT), ml	136.2±40.6	130.2±36.3a	124.9±35.4	125.9±38.2
Cortical volume, ml	92±29.8	85.3±29.8a	76.8±23.8	78.9±24.8
Medullary volume, ml	44.2±13.8	44.9±11.8	48.1±15.4	46.9±15.4
Cortical perfusion, ml/min per milliliter tissue	2.5±0.66	2.6±0.64	2.3±0.58	2.8±0.7a
Medullary perfusion, ml/min per milliliter tissue	0.95±0.26	1.15±0.39	0.74±0.19	0.9±0.26
Total RBF, ml/min	280.8±143	290.3±131.4	212.7±80.2	271.8±99.3a
Cortical blood flow, ml/min	238.5±129.9	237.4±116.7	177.3±72.3	229.2±89a
Medullary blood flow, ml/min	40.8±20.9	52.9±24a	35.3±12.5	42.6±16.1a
Single-kidney GFR, ml/min per kidney	34.3±13.1	34.4±13.9	29.5±13.2	30.9±12.4

Data are expressed as mean±SD. CT, computed tomography.

^aP<0.05 versus baseline (both paired t test and Wilcoxon signed-rank test).

Fractional Kidney Hypoxia Fell in MSC-Treated Kidneys

Tissue oxygenation levels defined both by cortical R2* values and fractional hypoxia (percent of whole kidney with R2*>30/s) did not differ between groups at baseline. Fractional hypoxia in the STK fell after 3 months in MSC-treated subjects (from 12.1% [3.3, 17.8] to 6.8% [1.8, 12.9]; P<0.04) Figure 2B, whereas no change was observed in the medically-treated group, from 10 (6.3, 25.1) to 9.6 (2.4, 37.7) (P=0.3) (Supplemental Table 1). Representative blood oxygen level–dependent (BOLD) images (R2* parametric maps) illustrating the change in hypoxia in an STK before and after MSC injection are illustrated in Figure 2A.

Figure 2.

MSC infusion decreased the levels of hypoxia in STKs. (A) Individual example of BOLD images (R2* parametric maps depicting effects of deoxyhemoglobin) illustrating the change in hypoxia in STK before and after MSC injection (left and right). There were lower R2* levels associated with hypoxia after MSC injection in both the cortical and medullary regions. (B) Fractional hypoxia levels in STK fell significantly after MSC treatment (P=0.04) (Supplemental Table 1). IQR, interquartile range.

The rise in cortical and total tissue perfusion and RBF were of similar magnitude for both doses of MSC infused (Figure 3).

Figure 3.

Similar magnitude for both doses of MSC on RBF and perfusion. Medullary, cortical, and total RBF measurements before and 3 months after intra-arterial infusion of autologous adipose-derived MSC. Both low dose (1.0 × 10⁵ cells/kg) and higher dose (2.5 × 10⁵ cells/kg) of MSCs were associated with a rise in cortical and total perfusion and blood flow of similar magnitude. These changes were evident in both STK and CLK. No such changes were evident in patients undergoing medical therapy only.

Renal Vein Levels of Vascular Endothelial Growth Factor Decreased after MSC Treatment

Renal vein levels of vascular endothelial growth factor (VEGF-C) decreased 3 months after MSC treatment compared with baseline (P=0.01) both at the STK and CLK (Figure 4). There were no such changes in the medically treated group. Renal vein levels of VEGF-A and inflammatory cytokines including IL-6, IFN-γ, TNF-α, monocyte chemoattractant protein-1 (MCP-1), and TGF-α tended to decrease in both kidneys after MSC treatment but did not reach statistical significance.

Figure 4.

Renal vein levels of VEGF-C decreased after MSC treatment. Renal vein levels of VEGF-C decreased 3 months after MSC treatment both in the STK and CLK (P<0.05). IQR, interquartile range.

Discussion

The results of this “first-in-man” phase 1/2A study indicate that intra-arterial infusion of autologous adipose tissue–derived MSCs in patients with atherosclerotic RVD increased cortical perfusion and RBF after 3 months, despite unchanged patency of the renal artery. Increased kidney perfusion was associated with measurable reduction in tissue fractional hypoxia and stabilization of GFR. MSC infusion was safe and well tolerated over the study follow-up period, with no identified adverse events related to MSC treatment. Serial safety laboratory tests demonstrated transient, minor changes in leukocyte counts, platelets, and CRP, all of which resolved by the return study visit at 3 months. Although our study was designed primarily to assess safety, these data also identified cortical hemodynamic effects associated with MSC treatment. These included the rise in renal cortical blood flow and perfusion in both the STK and nontreated kidneys at 3 months after MSC treatment. The reduction in hypoxia observed in the STK provided an independent measurement consistent with increased blood flow and tissue oxygenation. Whether these changes reflect new vessel formation (angiogenesis), redistribution of intrarenal flows, and/or altered intrarenal arterial shunting cannot be established with these data. Patients treated with intrarenal MSC and medical therapy had stable filtration, as reflected by the 3-month percent change in STK-GFR (−3%) compared with the medical treatment alone (−24%). To our knowledge, this is the first human experience with intra-arterial administration of cell-based therapy into ischemic kidneys.

Renal revascularization alone often fails to restore kidney function in atherosclerotic RVD, as reported in multiple recent clinical trials.^9,10 Studies of single-kidney GFR beyond stenotic lesions demonstrate a loss of filtration during medical therapy, which may be obscured by increased filtration in the CLK.^11–13 Our experimental studies in swine models of RVD demonstrate loss of microvascular structures¹⁴ that is magnified in the atherosclerotic environment^2,15,16 and correlates with loss of GFR.^6,17 Loss of cortical structural integrity appears in part related to oxidative stress and inflammation,¹⁴ which do not reverse after revascularization alone.^4,6, This is consistent with data from human STKs that release higher levels of inflammatory cytokines (including NGAL and TNF-α) and “homing” signals that attract reparative progenitor cells under some conditions.^4,18,19 Despite these signals, reparative mechanisms in human RVD usually are insufficient to restore vascular and tubular integrity after restoring vessel patency alone. In these studies we sought to evaluate the safety of infusing autologous MSC into the renal artery of human subjects with an ischemic environment. Results of our study in which inflammatory cytokines tended to decline after MSC treatment suggest that reparative and immunomodulatory properties of MSCs may partially abrogate vascular insufficiency and inflammatory injury pathways in the kidney that lead to progressive decline in kidney function. These results are consistent with data obtained in experimental large animal models.²⁰

The rise in RBF and perfusion after MSC treatment might be related to MSC angiogenic properties and the active secretion of the proangiogenic factors by MSC.^21,22 Improvements in the renal microcirculation after MSC treatment in experimental studies have been attributed to increased renal expression of the proangiogenic factor VEGF.⁷ Angiogenesis and restoration of flow to the ischemic tissue are particularly important to mitigate hypoxia and potentially improve the clinical course of RVD. In addition, MSC administration is thought to decrease oxidative stress⁷ and thereby increase the efficiency of oxygen utilization in the kidney.²³ Remarkably, and consistent with animal experiments,²⁴ our study showed that MSC treatment was also associated with increased cortical perfusion and RBF in the untreated CLKs. There are no methods currently for tracking the exact location of MSCs in human subjects. Using fluorescent markers in a pig model, labeled MSCs have been identified within both the STK and to a lesser extent in the CLK 4 weeks after injection.⁷ We and others have shown that CLKs express high levels of inflammatory cytokines (IL-6, TNF-α) and signs of fibrosis,^4,24–26 which were attenuated by MSC treatment.⁸ These observations are consistent with “cross-talk” signaling between kidneys and/or wider systemic effects of signaling and homing signals for MSCs, in addition to systemic effects of hypertension and atherosclerosis per se.^25,27 An additional effect observed after MSC treatment in this study was the reduction in fractional tissue hypoxia in the STK. Studies in patients with atherosclerotic RVD show that the STKs eventually develop higher levels of hypoxia compared with nonstenotic kidneys.^1,4, Chronic hypoxia triggers inflammation and tubulointerstitial fibrosis, stimulates an increase in the expression of VEGF,²⁸ and leads to chronic renal failure.^29,30 Our results underscore the potential for MSC treatment to reduce hypoxia and improve tissue oxygenation in the chronically ischemic kidney.

Importantly, the increase in RBF, perfusion, and renal oxygenation was not associated with improvement in glomerular filtration in these patients. GFR was preserved as compared with the medically treated group which declined slightly during follow-up, as previously observed.¹² It should be emphasized that angiotensin converting enzyme inhibitor/angiotensin receptor blocker therapy was continued throughout these protocol studies, in part because activation of the renin-angiotensin system affects tissue oxygenation^31,32 and BOLD magnetic-resonance imaging (MRI) measurements. Because no changes were made to the main renal arterial lesions, poststenotic arterial pressures likely remained low, rendering trans-capillary filtration pressures dependent upon the renin-angiotensin system. Hence, filtration was likely limited partly by removal of efferent arteriolar vasomotor tone by renin-angiotensin system blockade.

Expression of VEGF-C is upregulated by proinflammatory cytokines such as IL-1B and TNF.³³ Elevated levels of plasma VEGF-C are found in patients with vascular diseases associated with lymphangioleiomyomatosis,^34,35 and inflammatory diseases where the levels of VEGFs have been correlated to measures of endothelial dysfunction.³⁶ Our results after MSC treatment indicated decreased renal vein levels of VEGF-C, angiopoietin, and inflammatory cytokines both from the STK and CLK, consistent with an anti-inflammatory effect of MSCs associated with angiogenesis and increased RBF and perfusion.

Although advanced RVD can lead to renal hypoxia, previous studies showed that restoring vessel patency by revascularization alone fails to alter local inflammatory signals suggesting ongoing processes of tissue injury and inflammation.⁴ This study suggests that additional measures, such as intra-arterial MSCs, may partially abrogate those pathways. Recent experimental studies combining intrarenal infusion of MSCs and revascularization indicate that recovery of renal microvessels, blood flow, and glomerular filtration is possible in the STK.⁷

This study has limitations. It was an open-label, nonrandomized study, with a relatively limited number of patients. The medical treatment only group did not undergo angiography or arterial cannulation. For ethical reasons, we did not have a control group of healthy individuals treated with MSC. Although unlikely, there may have been effects related to the angiography or injection of material that caused effects attributed to the MSCs. Diabetic subjects were specifically excluded in this phase I/2A study. A longer follow-up period is needed to detect long-term effects.

Our results indicate that intra-arterial infusion of autologous MSC in patients with RVD is safe and well tolerated. MSC infusion at these doses increased cortical perfusion and RBF and reduced renal tissue hypoxia within STKs. These changes were associated with preserved STK-GFR as compared with a medically treated group in which STK-GFR declined over the same interval. These data underscore a potential adjunctive role for MSC in the management of ischemic renal disease. Further studies combining MSC with revascularization of the STK offer the potential to both restore large vessel patency and blood flow and to improve renal microcirculation in ischemic renal disease.

Concise Methods

Study Design and Patient Selection

In this first-in-man, open-label, single center, dose-escalation trial, we enrolled adult patients with significant RVD estimated by renal artery Doppler ultrasound velocity acceleration (average peak systolic velocity >300 cm/s) and/or magnetic resonance/computed tomography angiography with evident atherosclerotic stenosis (>60% lumen occlusion), and hypertension (systolic hypertension >155 mmHg and/or the use of at least two BP drugs) and/or with declining kidney function. Exclusion criteria included serum creatinine >2.5 mg/dl, diabetes mellitus, allergy to furosemide or iodinated contrast, pregnancy, kidney transplant, malignancy, or recent history of a major cardiovascular event within 6 months. Enrolled patients were admitted into the Clinical Research Unit at St. Mary’s Hospital, Rochester, Minnesota between June of 2013 and April of 2016. All patients received medical therapy consisting of agents blocking the renin-angiotensin system during these studies (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers). Twenty-eight patients with RVD were included in the analysis: 14 were treated with standardized medical therapy plus a single intra-arterial infusion of autologous MSCs in the renal artery (MSC-treated group). The first seven were assigned to a low dose (1.0 × 10⁵ cells/kg) and the next seven patients to a higher dose (2.5 × 10⁵ cells/kg), on the basis of animal studies and investigational new drug (IND) #15082 with the Food and Drug Administration (FDA).⁷ When bilateral stenoses were identified (n=6), only the kidney with the most severe stenosis was infused with MSC. The other 14 patients who participated in the identical protocol without MSC were treated with standardized medical therapy alone (medically treated group) and were matched for age, GFR, sex, and stenosis severity. Informed, written consent was obtained as approved by the institutional review board of the Mayo Clinic in compliance with the Declaration of Helsinki. MSC preparation and administration were performed under IND# 15082 approved by the FDA. The study was registered with ClinicalTrials.gov (NCT02266394); https://clinicaltrials.gov/ct2/show/NCT02266394.

MSC Isolation, Preparation, and Safety Evaluation

Six weeks before planned administration, a subcutaneous abdominal fat biopsy sample (approximately 0.5–2 g) was obtained under sterile conditions. Enzymatic digestion of the fat was followed by selection and expansion of plastic adherent cells. Cells were cultured in Advanced MEM (Gibco Cat #12492021) supplemented with human platelet lysate (PLTMax; Mill Creek Life Sciences) over 2 weeks using good manufacturing practices as previously described until a sufficient number of cells were obtained for each treatment protocol.³⁷ Release criteria for administration after final passage included sterility testing using anaerobic and aerobic culture, endotoxin, mycoplasma, karyotype, and FACS for surface markers characteristic of MSC.^37,38

Interventions and Inpatient Study Protocol

Patients participated in this study during a 3-day inpatient protocol on two occasions (3 months apart) in the clinical research unit as previously described.⁴ Dietary intake was regulated at 150 mEq of sodium with an isocaloric diet prepared on site. The first study day included measurement of urinary sodium excretion and GFR by iothalamate clearance (iothalamate meglumine, Conray, Mallinckrodt) over three 30-minute timed collection periods after oral hydration (20 ml/kg).^39,40 Single kidney–GFR was determined by apportioning the measured iothalamate clearance by percentage of blood flow for each kidney. BP was measured by automated oscillometric recordings including three values taken three times daily.

Renal Oxygenation Measured by BOLD MRI

On the second day, BOLD MRI examinations were performed on a (GE Twin Speed Signa EXCITE) 3.0T system (GE Medical Systems, Waukesha, WI) using a 12-channel torso phased array coil.^1,41,42 The BOLD MRI is a measure of deoxyhemoglobin in the blood—because the oxygen tension (pO2) of capillary blood generally is thought to be in equilibrium with the surrounding tissue, changes estimated by BOLD MRI are interpreted as changes in tissue pO2⁴³

Cortical and Medullary Tissue Perfusion and Blood Flow Measured by MDCT

On the third study day, the common femoral vein was cannulated with a 6F sheath and blood samples drawn from the right and left renal veins with a 5F pigtail Cobra catheter (Cook, Inc., Bloomington, IN). The catheter was then advanced into the right atrium for central venous injection of contrast for flow studies using MDCT. For assessment of perfusion MDCT imaging was obtained using a dual-source 64-slice helical MDCT scanner (SOMATOM Definition, Siemens Medical Solutions) after a bolus injection of iopamidol 370 (0.5 ml/kg). Kidney volume study was performed in the helical mode to determine both cortical and medullary regional volumes.⁴⁴

MSC Infusion, Laboratory Testing, and Safety Monitoring

After completing CT imaging, patients were returned to the angiography suite where standard aortic cannulation was performed through the femoral artery. Heparin (4000 U) was administered intravenously and the stenotic renal artery then selectively cannulated and imaged, after which MSCs suspended in 10 ml of Lactated Ringer’s solution were manually infused distal to stenosis over 5 minutes. Follow-up angiography was obtained once the infusion was complete, and the catheter removed. Patients remained hospitalized for observation for 24 hours after MSC administration. Blood samples were obtained the following day, day 7, and monthly until the 3-month return visit peripheral for complete blood count, CRP, urine cytology, lactate dehydrogenase, and markers of renal injury (e.g., NGAL). Renal vein blood samples for VEGF-C, angiopoietin, and inflammatory cytokine levels (including IL-6, IFN-γ, TNF-α, and MCP-1) were obtained from the STK and CLK renal vein of all patients, as previously described.^4,26

Statistical Analyses

Results were expressed using mean values and SD or median values (interquartile range), as appropriate. Qualitative variables were expressed as number (percentage). Comparisons between the two groups of patients with RVD were performed using two-sample t tests with unequal variance (or the Wilcoxon rank-sum test for skewed data) for continuous variables, and a chi-squared test or Fisher exact test for categoric variables as appropriate. Comparisons between two kidneys within the same individuals and repeated measurements for specific kidneys within individuals before and after treatment were performed using paired t tests. Percent (%) change in STK-GFR was calculated as: ([(3 months STK-GFR−baseline STK-GFR)/baseline STK-GFR] × 100%). Statistical significance was accepted for P≤0.05. Statistical analysis was performed using JMP software package version 8.0 (SAS Institute Inc., Cary, NC). Complete and detailed methods are provided as Supplemental Material.

Disclosures

None.